

1 ***Helicobacter pylori* promotes colorectal carcinogenesis by**
2 **deregulating intestinal immunity and inducing a mucus-degrading**
3 **microbiota signature**

4
5 **Anna Ralser¹, Alisa Dietl¹, Sebastian Jarosch¹, Veronika Engelsberger¹,**
6 **Andreas Wanisch¹, Klaus Peter Janssen², Michael Vieth³, Michael Quante^{4,5},**
7 **Dirk Haller^{6,7}, Dirk H. Busch^{1,9}, Li Deng⁸, Raquel Mejías-Luque^{1,9}†, Markus**
8 **Gerhard^{1,9}†***

9 **Affiliations:**

10 ¹ Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, 81675,
11 Germany.

12 ² Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Surgery, Munich,
13 81675, Germany.

14 ³ Institute of Pathology, Friedrich-Alexander University Erlangen-Nuremberg, Klinikum Bayreuth, Bayreuth, 95445,
15 Germany.

16 ⁴ Klinik für Innere Medizin II, Gastrointestinale Onkologie, Universitätsklinikum Freiburg, Freiburg, 79106,
17 Germany.

18 ⁵ Klinik und Poliklinik für Innere Medizin II, Technical University of Munich, Munich, 81675, Germany.

19 ⁶ Chair of Nutrition and Immunology, Technical University of Munich, Freising-Weihenstephan, 85354, Germany.

20 ⁷ ZIEL Institute for Food & Health, Technical University of Munich, Munich, 80333, Germany

21 ⁸ Institute of Virology, School of Medicine, Helmholtz Center Munich, Technical University of Munich, Garching,
22 85748, Germany.

23 ⁹ German Center for Infection Research (DZIF), Munich Partner Site, Munich, 81675, Germany.

24
25 *Corresponding author. Email: markus.gerhard@tum.de

26 † These authors contributed equally to this work

27
28

29 **ABSTRACT**

30 **OBJECTIVE**

31 *H. pylori* infection is the most prevalent bacterial infection worldwide. Besides being the most
32 important risk factor for gastric cancer development, epidemiological data show that infected
33 individuals harbor a nearly two-fold increased risk to develop colorectal cancer (CRC).
34 However, a direct causal and functional connection between *H. pylori* infection and colon
35 cancer is lacking.

36 **DESIGN**

37 We infected two *Apc*-mutant mouse models and C57BL/6 mice with *H. pylori* and conducted
38 a comprehensive analysis of *H. pylori*-induced changes in intestinal immune responses and
39 epithelial signatures via flow cytometry, chip cytometry, immunohistochemistry and single cell
40 RNA sequencing. Microbial signatures were characterized and evaluated in germ-free mice
41 and via stool transfer experiments.

42 **RESULTS**

43 *H. pylori* infection accelerated tumor development in *Apc*-mutant mice. We identified a
44 unique *H. pylori*-driven immune alteration signature characterized by a reduction in
45 regulatory T-cells and proinflammatory T-cells. Furthermore, in the intestinal and colonic
46 epithelium, *H. pylori* induced pro-carcinogenic STAT3 signaling and a loss of goblet cells,
47 changes that have been shown to contribute - in combination with pro-inflammatory and
48 mucus degrading microbial signatures - to tumor development. Similar immune and epithelial
49 alterations were found in human colon biopsies from *H. pylori*-infected patients. Housing of
50 *Apc*-mutant mice under germ-free conditions ameliorated, and early antibiotic eradication of
51 *H. pylori* infection normalized the tumor incidence to the level of uninfected controls.

52 **CONCLUSIONS**

53 Our studies provide evidence that *H. pylori* infection is a strong causal promoter of colorectal
54 carcinogenesis. Therefore, implementation of *H. pylori* status into preventive measures of
55 CRC should be considered.

56

57 INTRODUCTION

58 *Helicobacter pylori* infection affects more than half of the world's population and it is a main
59 risk factor for gastric cancer. *H. pylori* induces a number of alterations in the gastric mucosa
60 that together result in neoplastic transformation of the epithelium. Thus, *H. pylori* infection
61 first triggers a complex plethora of immune cascades, directed towards *H. pylori* and
62 orchestrated by the bacterium itself, which originate from priming at the Peyer's Patches and
63 the mesenteric lymph nodes of the small intestine (1, 2). The major pro-inflammatory
64 response towards *H. pylori* consists of a mixed Th1 and Th17 response (1), and is to a large
65 extent related to the presence and activity of a type 4 secretion system (T4SS) (3), which
66 mediates translocation of the oncogenic and highly immunogenic protein CagA into gastric
67 epithelial cells (4). This leads to chronic inflammation and results in the activation of pro-
68 inflammatory signaling pathways such as activating Nuclear Factor- κ B (NF- κ B) and signal
69 transducer and activator of transcription 3 (STAT3) signaling, which are major drivers of *H.*
70 *pylori* induced gastric carcinogenesis (5). However, *H. pylori* has evolved counter
71 mechanisms in order to establish and maintain chronic infection, for example by
72 reprogramming dendritic cells (DCs) to induce regulatory T-cells (Treg) (6, 7), which not only
73 counterbalance the local pro-inflammatory response in the stomach (8), but are also involved
74 in protection from allergic asthma (9). Interestingly, this tolerogenic reprogramming of DCs is
75 partially mediated by CagA, via activation of STAT3 (7). Finally, alterations in gastric
76 microbiota are observed upon infection, which seem to contribute to the deleterious events
77 leading to gastric cancer following *H. pylori* infection (10). This idea is supported by studies
78 using animal models as the insulin-gastrin (INS-GAS) mice, which showed more severe
79 gastric pathology and early development of neoplasia when colonized with *H. pylori* and
80 carrying normal commensal microbiota compared to germ free INS-GAS mice infected with
81 the bacterium (11).

82 Although *H. pylori* infection is limited to the stomach, accumulating epidemiological data
83 indicate an association between *H. pylori* infection and different extra-gastric diseases (12).
84 Among those, a higher risk of colorectal cancer has been reported to be associated with *H.*
85 *pylori* infection status (13). However, the mechanisms that could explain this increased risk
86 have not been elucidated.

87 In our study, we identify *H. pylori*-specific alterations in gut homeostasis that contribute to
88 colorectal carcinogenesis in mouse models of CRC as well as in human samples, and are
89 reversible upon *H. pylori* eradication. These findings provide a basis for assessing *H. pylori*
90 status not only for gastric, but also for colon cancer prevention programmes.

91 **RESULTS**

92

93 ***H. PYLORI* PROMOTES INTESTINAL CARCINOGENESIS IN APC MOUSE**
94 **MODELS**

95 To determine whether *H. pylori* infection promotes the development of tumors in the lower
96 gastrointestinal tract, we infected *Apc*^{+/*min*} and *Apc*^{+/*1638N*} mice for different time periods (Fig.
97 S1A and Fig. S1B). Unexpectedly, *Apc*^{+/*min*} mice were highly susceptible to the infection, with
98 only 60% of the mice surviving after 12 weeks of *H. pylori* infection (Fig. 1A). An increased
99 tumor burden in the small intestine and colon was observed in infected *Apc*^{+/*min*} mice
100 compared to uninfected controls (Fig. 1B and 1C). Similar results were observed in *Apc*^{+/*1638N*}
101 mice, which not only developed twice as many tumors after infection, but also showed larger
102 tumors in the small intestine (Fig. S1C). Notably, in *Apc*^{+/*1638N*} mice, colonic tumors were
103 exclusively detected in *H. pylori* infected mice (Fig. S1C). These observations demonstrate
104 that *H. pylori* infection promotes the development of intestinal and colonic tumors in tumor
105 prone mice, while exclusively infecting the stomachs of these mice (Fig S1B).

106

107 ***H. PYLORI* INFECTION INDUCES A PRO-INFLAMMATORY RESPONSE IN THE**
108 **INTESTINE**

109 Manipulation of host's T cell immune responses characterizes *H. pylori* infection and is one
110 the main mechanisms contributing to gastric carcinogenesis. To assess whether alterations
111 in intestinal immunity could be related to the increased tumor burden observed in infected
112 *Apc* mutant mice, we first analyzed lymphocyte infiltration in the small intestine of *Apc*^{+/*min*} and
113 *Apc*^{+/*1638N*} mice upon infection. Recruitment of intraepithelial CD3⁺ T cells to small intestine
114 and colon was increased upon *H. pylori* infection (Fig. 2A and Fig. S2A), which was also
115 confirmed by flow cytometric analysis of T-cells (Fig. S2B and 2C). Furthermore, this
116 revealed a shift towards more CD8⁺ and less CD4⁺ T cells upon infection (Fig. S2D). In
117 addition, the abundance and protein level of Foxp3⁺ regulatory T (Treg) cells was reduced in
118 the small intestine from infected mice compared to uninfected controls, as detected by flow
119 cytometry (Fig. 2B and Fig. S2E).

120 To further explore the underlying mechanisms promoting intestinal tumorigenesis upon
121 *H. pylori* infection independently from tumor-prone backgrounds, we infected wild type
122 C57BL/6 mice (wt) and analyzed immune responses (Fig. S2F). An increased number of
123 intraepithelial CD3⁺ T cells was also observed in the small intestine as well as in the colon of
124 *H. pylori* infected wt mice compared to uninfected controls (Fig. 2C). Contrasting the
125 balanced immune phenotype observed in the stomach (Fig. 2C and Fig. S2G), this was
126 accompanied by a reduction in Foxp3⁺ Treg cells (Fig. 2D and Fig. S2G). Multiplexed

127 ChipCytometry corroborated an overall reduction of Treg cells, and additionally revealed their
128 compartmentalization within the lamina propria in infected colonic tissue (Fig. 2E).

129 We next confirmed the specificity of these T cells for *H. pylori* by restimulating lamina propria
130 CD4⁺T cells with *H. pylori* lysate and measuring the release of the pro-inflammatory cytokine
131 IL-17A, which has been previously described to be one of the main players in the immune
132 response to *H. pylori* (1). A specific IL-17A/CD4⁺T cell response was observed in infected
133 C57BL/6 and *Apc*^{+/^{min} mice (Fig. S2H).}

134 To characterize in depth the specific intestinal immune response elicited by gastric *H. pylori*,
135 we investigated the immune cell compartment on a single cell level by performing 10X single-
136 cell RNA sequencing (scRNAseq). We isolated and sorted single CD45⁺ immune cells of
137 intestinal and colonic tissue from *Apc*<sup>+/^{min} mice and littermate wild type controls that had been
138 infected for 12 weeks with *H. pylori*, and compared them to non-infected controls (Fig. S2I).</sup>

139 Unsupervised clustering identified 16 clusters according to their transcriptional profiles, which
140 are visualized using Uniform Manifold Approximation and Projection (UMAP) (14) (Fig 2F
141 and Fig. S2J) and were annotated based on known marker genes (Fig. S2K).

142 To further characterize the Treg cell compartment, we subclustered and annotated Treg
143 cells, which resulted in three subclusters: activated Treg cells (act. Tregs); peripherally
144 derived Treg cells (pTregs), characterized by high RORyt expression; and thymus derived
145 Treg cells (tTregs), characterized by GATA3 expression (15, 16) (Fig. 2G and Fig. S2L). We
146 then computed a Treg effector score (17) (Fig. 2H), and found significantly increased Th17
147 differentiation genes in infected act. Tregs (Fig. 2H), indicating that *H. pylori* infection
148 reprograms Treg cells into potentially pathogenic Foxp3⁺ IL-17A⁺ T cells.

149 Finally, to understand cell dynamics of T cells in infected mice, we calculated RNA velocity
150 vectors, which predict future states of individual cells based on ratios of spliced and
151 unspliced mRNAs (18). In line with our previous findings, when looking at the CD4 clusters, it
152 was apparent that less CD4 cells were projected towards CD4 Treg cells in infected *Apc*
153 mice (Fig. S2M).

154 In summary, our results show that *H. pylori* infection induces a *H. pylori* specific pro-
155 inflammatory immune response in the small intestine and colon of infected mice, that is
156 characterized by loss of regulatory T cells and their differentiation into Foxp3⁺ IL-17A⁺T cells.

157

158 **ACTIVATION OF CARCINOGENIC SIGNALING PATHWAYS AND LOSS OF** 159 **GOBLET CELLS CHARACTERIZE THE INTESTINAL EPITHELIAL RESPONSE** 160 **TO *H. PYLORI* INFECTION**

161 Considering the alterations induced by *H. pylori* in intestinal immune cells independently of
162 APC mutations in wild type mice, we analyzed the effect on signaling pathways putatively
163 mediating the pro-carcinogenic effects of *H. pylori* infection in the epithelium. Therefore, we

164 assessed transcriptomic profiles of EPCAM⁺ epithelial cells from *Apc*<sup>+/^{min} mice in our
165 scRNAseq data (Fig. S2I). Unsupervised clustering revealed 15 clusters according to their
166 transcriptional profiles, which were visualized as UMAP (Fig. 3A and Fig. S3A) and
167 annotated based on known marker genes (Fig. S3B).</sup>

168 Pseudo-spatial distribution of epithelial cells along the crypt-villus axis were computed to
169 confirm correct annotation of cell types (19, 20) (Fig. S3C).

170 Here, we specifically explored signaling pathways associated with CRC initiation and
171 development, namely STAT3 and NF-κB. Notably, these pathways also orchestrate key
172 inflammatory mechanisms in inflammation-driven colon cancer and have been extensively
173 related to *H. pylori* infection (21-23). We computed a score of genes involved in the Jak-
174 STAT signaling pathway, which revealed significantly higher scores in enterocytes and stem
175 cells of wild type and enterocytes of *Apc*<sup>+/^{min} mice upon *H. pylori* infection (Fig. 3B, Fig. S3D).
176 Similarly, when assessing NF-κB signaling in enterocytes, higher scores were observed upon
177 *H. pylori* infection (Fig. S3E).</sup>

178 As it has been shown that activation of epithelial STAT3 favors recruitment of lymphocytes,
179 while inhibiting infiltration of Treg cells in the colon (24), we confirmed hyperactivation of
180 STAT3 in tissue samples from *H. pylori* infected wild type (Fig. 3C) and *Apc* mutant mice
181 (Fig. 3D), which was accompanied by enhanced proliferation as detected by Ki67 staining
182 (Fig. 3C).

183 Given that a functional intestinal barrier is depending on mucus replenishment by goblet
184 cells, we next assessed their status by Periodic acid Schiff (PAS) staining. We observed
185 reduced number of mucus producing cells in the small intestine and in the colon of *H. pylori*
186 infected wild type (Fig. 3C) and *Apc* mutant mice (Fig. 3E) compared to uninfected controls.

187 To explore in depth the effects of *H. pylori* infection on the goblet cells, we clustered and
188 annotated goblet cells in our scRNAseq data set based on goblet cell differentiation markers
189 (25). This revealed immature, characterized by high expression of *Tff3*; intermediate, highly
190 expressing *Oasis*; and terminal goblet cells, with high expression of *Muc2* and *Klf4* (Fig. S3F
191 and Fig. S3G). Maturation states were distinctly affected by *H. pylori* infection, with a switch
192 to less differentiated goblet cells (Fig. S3H). To assess goblet cell functionality, we assessed
193 the expression of antimicrobial peptide genes *Reg3b* and *Reg3g*, which are known to play a
194 role in response to pathogens and inflammation (26). We found them to be reduced upon *H.*
195 *pylori* infection (Fig. S3I). These findings are consistent with a compromised intestinal barrier
196 integrity induced by *H. pylori* infection, independent of *APC* status.

197 To explain the absolute loss of goblet cells we observed in infected mice, we studied cellular
198 dynamics of goblet cells by means of RNA velocities. In the colon, we observed less
199 directionality from the stem cell cluster towards the goblet cell cluster, and at the same time a
200 higher projection towards the colonocyte cluster upon *H. pylori* infection (Fig. S3J), in

201 contrast to the small intestinal goblet cell cluster, where cell dynamics seem to be restricted
202 to the goblet cell cluster itself. When assessing the expression of *Atoh1*, which is known to
203 drive terminal differentiation into the secretory lineage (27), in stem cells of both small
204 intestine and colon, a significantly lower expression was found upon *H. pylori* infection (Fig.
205 S3K). These findings indicate a skewed differentiation of stem cells rather into unspecialized
206 colonocytes than into goblet cells.

207 Together, these results indicate that *H. pylori* induces carcinogenic signaling pathways and
208 has a detrimental impact on mucus producing goblet cells in the small intestine and colon of
209 wt and *Apc* mutant mice.

210

211 ***H. PYLORI* INFECTION FAVORS THE PRESENCE OF MUCUS-DEGRADING** 212 **MICROBIOTA**

213 Microbiota alterations and aberrant presence of certain bacterial species in the small
214 intestine have been related to the development of CRC (28). This could be an additional
215 mechanism by which *H. pylori* contributes to intestinal carcinogenesis, since *H. pylori*
216 infection has been shown to alter microbiota signatures (29). Therefore, we assessed to
217 which extent *H. pylori* infection influenced small intestinal and colonic microbial composition
218 by performing 16S RNA sequencing. While we found significantly increased abundance of
219 *Helicobacter* spp. in the stomach, we did not detect *H. pylori* in intestine and colon (Fig.
220 S4A). When comparing the microbiota in caecum and colon of infected and non-infected
221 mice via taxonomic profiling, we observed apparent changes at phylum level upon *H. pylori*
222 infection (Fig. 4A). Furthermore, we found signs of decreased α -diversity in small intestine
223 upon *H. pylori* infection (Fig. S4B) as well as significantly different β -diversity in caecum,
224 stool and small intestine between non-infected and infected mice (Fig. S4C). Differential
225 abundance testing revealed *Akkermansia* spp. to be enriched in infected wt mice (Fig. S4D,
226 Fig. 4B). When exploring the data for further species sharing the mucus-degrading
227 characteristics of *Akkermansia* spp., we found an increase in *Ruminococcus* spp. (Fig. 4B
228 and Fig. S4D). The abundance of both species was also higher in *Apc* mutant mice upon *H.*
229 *pylori* infection (Fig. 4C and 4D).

230 Together, *H. pylori* alters the microbiota of the lower gastrointestinal tract and induces
231 distinct mucus-degrading signatures in both wt and *Apc* mutant mice.

232

233 ***H. PYLORI* INDUCED COLORECTAL CARCINOGENESIS IS PREVENTED BY** 234 **ERADICATION**

235 The interplay between a pro-inflammatory response and activation of pro-carcinogenic
236 signaling, accompanied by alterations in microbiota characterized *H. pylori*-driven intestinal
237 tumorigenesis. To dissect the contribution of inflammation in the absence of microbiota, we

238 infected $Apc^{+/1638N}$ mice under germ-free conditions (Fig. S5A and 5B). We observed similar
239 immune alterations as in specific-pathogen free (SPF) mice, namely increased CD3⁺ T cell
240 infiltration and reduction of Treg cells in small intestine and colon (Fig. 5A, Fig. S5D and 5B).
241 In contrast, germ-free mice barely showed activation of STAT3 signaling, and no reduction of
242 goblet cells upon *H. pylori* infection (Fig. 5C and 5D, Fig. S5D). Finally, we still observed a
243 higher tumor number in *H. pylori* infected germ-free mice, albeit not significant (Fig. 5E). In
244 order to ultimately assess the contribution of *H. pylori* induced changes in microbiota to
245 intestinal carcinogenesis, we performed a stool transfer experiment. Stool was obtained from
246 4 different groups, namely SPF non-infected and *H. pylori* infected $Apc^{+/1638N}$ and $Apc^{+/+}$ mice,
247 respectively, and transferred into germ-free $Apc^{+/1638N}$ mice (Fig. S5C). Higher tumor
248 numbers in stool recipients from *H. pylori* infected mice were found, which was already
249 evident in $Apc^{+/+}$ mice and further enhanced in an $Apc^{+/1638N}$ background (Fig. 5F). This
250 indicates a strong contribution of *H. pylori*-induced changes in microbiota to the tumor
251 phenotype and suggests, that *H. pylori*-induced carcinogenesis in the small intestine and
252 colon is a multifactorial process involving the interplay of the pro-inflammatory immune
253 response, alterations in microbiota and procarcinogenic signaling. Therefore, we next sought
254 to determine whether eradication of *H. pylori* infection could abrogate the carcinogenic
255 process, by treating the mice with a triple therapy regimen consisting of clarithromycin,
256 metronidazole and omeprazole (30), reflecting the “Italian triple therapy” regimen also used
257 in infected patients to eradicate *H. pylori* (Fig. 5G and Fig. S5E). Importantly, we found that
258 after antibiotic eradication, tumor burden was at the same levels as in uninfected controls
259 (Fig. 5H). To delineate that the underlying changes in the intestinal immune response were
260 directly induced by *H. pylori* infection and independent of mutated *Apc*, we analyzed the
261 effect of *H. pylori* eradication on C57Bl/6 mice (Fig. 5G), and found a lower CD3⁺ T cell
262 infiltration in the stomach (Fig. S5F), small intestine and colon (Fig. 5I, Fig. S5G) compared
263 to infected mice at 4 and 12 weeks post eradication. The percentage of Treg cells was
264 initially reduced in eradicated mice 4 weeks after treatment, while 12 weeks post-treatment,
265 the percentage of FoxP3⁺ T cells was observed to recover (Fig. 5J). A specific IL-17A/CD4⁺T
266 cell response was observed in infected mice, which was initially lost after eradication therapy,
267 but then reappeared after longer recovery time (Fig. 5K), supporting the specificity of the
268 response to *H. pylori*, based on the given antigen encounter and response also in eradicated
269 mice. Importantly, the clearance of infection resulted in normalization of STAT3 activation
270 and the number of PAS positive cells (Fig. 5L and Fig. S5G), confirming that *H. pylori* is
271 specifically responsible for these changes.

272 In summary, our results demonstrate that *H. pylori* directly enhances colon carcinogenesis by
273 shaping intestinal and colonic immune responses and inducing profound changes in
274 intestinal/colonic microbiota and epithelial homeostasis. Eradication of *H. pylori* infection

275 prevents its tumor-promoting effects also in the colon, providing a possible additional
276 strategy to reduce CRC burden.

277

278 ***H. PYLORI* ALTERS COLONIC HOMEOSTASIS IN HUMAN**

279 Our mouse models showed that *H. pylori* affects intestinal and colonic homeostasis at
280 different cellular and molecular levels, which can ultimately enhance tumor development. To
281 determine whether these effects were also observed in humans, we analyzed immune
282 signatures in a cohort of 154 human colon tissue samples. Based on immune responses and
283 histology of the stomach, we stratified samples according to *H. pylori* status into currently
284 (actively) infected and eradicated patients. We found that *H. pylori*-actively infected as well
285 as eradicated individuals showed higher infiltration of CD3⁺ T cells in the colon compared to
286 uninfected subjects (Fig. 6A). Using endoscopy-derived colon biopsies, we further
287 characterized T cell responses by flow cytometry, which revealed tendencies towards more
288 CD3⁺ T cells in the colonic mucosa of currently infected patients (Fig. S6A). In contrast, CD4⁺
289 and CD8⁺ subsets were not affected by *H. pylori* status (Fig. S6B). Notably, the number of
290 FoxP3⁺ cells in the colonic mucosa was lowest in the currently infected group, whereas
291 eradicated patients seem to level with negative controls (Fig. 6C). The overall loss of Tregs
292 was confirmed via ChipCytometry (Fig. 6B), which additionally showed that intraepithelial
293 localization of Tregs is almost lost in colon samples from *H. pylori* infected individuals (Fig.
294 6B and Fig. S6C).

295 We next focused on the epithelial compartment and, in concordance with our findings in mice
296 and our eradication experiments, found a higher number of p-STAT3 positive epithelial cells
297 and a concomitant loss of mucus producing cells in the colon of currently infected subjects,
298 which was attenuated in eradicated patients (Fig. 6A).

299 Finally, we assessed microbial changes in stool of patients and found a difference in β -
300 diversity between actively *H. pylori* infected and negative patients ($p=0.062$), but not between
301 *H. pylori* eradicated and negative patients ($p=0.552$) (Fig. 6D). In contrast, we neither
302 detected significant changes in alpha-diversity (Fig. S6D) nor in Firmicutes to Bacteroidetes
303 ratio (Fig. S6E) between the 3 groups. Comparative microbiome profiling revealed
304 *Prevotellaceae* and *Peptostreptococcales*, which have been associated with CRC, to be
305 differentially abundant in *H. pylori* positive patients (Fig. S6F and Fig. S6G).

306 These results confirm that the immune and epithelial signatures identified in mouse models
307 upon *H. pylori* infection are also observed in humans, and are accompanied by changes in
308 microbiota compositions, which can further contribute to colon carcinogenesis. Furthermore,
309 the attenuated phenotype observed in *H. pylori* eradicated patients further supports *H. pylori*
310 status as an independent risk factor for CRC and simultaneously offers an option for CRC
311 prevention for those patients at risk.

312

313 DISCUSSION

314 Although selectively colonizing the stomach, chronic *H. pylori* infection is associated with
315 several extragastric diseases (31). Epidemiological data indicates an association between *H.*
316 *pylori* infection and a higher risk and aggressiveness of colorectal cancer (CRC), with an
317 odds ratio (OR) of 1.9 (32), an OR higher than for most other known risk factors, such as
318 smoking, alcohol and BMI (32). However, these epidemiological data have not yet been
319 confirmed experimentally, and a molecular mechanism by which *H. pylori* may promote CRC
320 remained elusive. We employed *Apc* mutant mouse lines (*Apc*^{+/-min} and *Apc*^{+/-1638N}) as surrogate
321 models for human CRC, and observed a nearly two-fold increase in tumor numbers in mice
322 infected with *H. pylori*, which coincides with the OR observed in epidemiological studies.
323 Remarkably, this increase was not only observed in the small intestine, where both models
324 usually show most tumors, but was especially evident in the colon. This prompted us to
325 decipher the potential mechanisms driving *H. pylori*-induced carcinogenesis in the small
326 intestine and colon.

327 The effects of *H. pylori* infection on other organs are best understood for the lung, where
328 chronic *H. pylori* infection imposes a regulatory immune signature that protects from asthma
329 disease (33). In contrast to these observations, we observed an *H. pylori* antigen-specific
330 pro-inflammatory Th17 mediated response in the small intestine and colon, which was not
331 balanced by an increase in Treg cells, as it occurs in the stomach or lung. The immune
332 response mounted towards *H. pylori* originates from Peyer's patches in the gut (2), which
333 may explain why *H. pylori* specific T cells also homed to intestinal and colonic mucosal sites.
334 Interestingly, IL-17 was not only found to be increased in *H. pylori* positive patients with
335 gastritis and gastric cancer (34), but also in CRC, where Th17 signatures, including RORC,
336 IL17, IL23 and STAT3, were linked to poorer prognosis (35). Still, it was surprising to observe
337 a loss of intestinal Treg cells, which also contrasts the balanced immune response usually
338 observed in the stomach upon *H. pylori* infection. Additionally, we found that in the lower GI
339 tract, Tregs were reprogrammed to upregulate Th17 differentiation markers. Murine and
340 human studies have demonstrated that Treg cells can be reprogrammed to a distinct
341 population, Foxp3⁺/IL17⁺T cells, phenotypically and functionally resembling Th17 cells (36).
342 Particularly in CRC, the presence of Foxp3⁺/IL17⁺T cells has been reported to be increased
343 in the mucosa and peripheral blood of chronic colitis patients as well as in colorectal tumors
344 (37). Foxp3⁺/IL17⁺ cells were shown to promote the development of tumor-initiating cells by
345 increasing the expression of several CRC-associated markers such as CD44 and epithelial
346 cell adhesion molecule EPCAM in bone marrow-derived mononuclear cells (38). Thus, the
347 pro-inflammatory Th17 response elicited by *H. pylori*, especially the differentiation of Treg
348 cells to a Th17 phenotype, may constitute one of the major mechanisms enhancing tumor

349 development. This is in line with literature showing that altered T cell homeostasis is a key
350 event during colorectal carcinogenesis, not only driving tumor development and progression,
351 but also determining treatment response of CRC patients (39).

352 Mutations in the gene encoding adenomatous polyposis coli (*APC*) are the most frequent
353 driver mutations leading to sporadic CRC, together with mutations in *TP53* and *KRAS* (40,
354 41). Pro-inflammatory and proliferative signaling pathways such as STAT3, NF- κ B and WNT
355 signaling, activated by signals derived from epithelial and immune cells, drive chronic
356 inflammation, a known mechanism contributing to CRC (23, 42). CRC risk is markedly
357 increased in patients with chronic inflammatory bowel disease (IBD) , with the risk rising with
358 the duration of disease, from 8.3% after 20 years, to 18.4% after 30 years (43).
359 Mechanistically, besides immune signaling by Th17 cells, activation of pro-inflammatory
360 signaling pathways as well as altered microbiota, contribute to the pathogenesis of colitis-
361 associated cancer (44).

362 The strong pro-inflammatory response induced locally by *H. pylori* in the small intestine was
363 accompanied by the activation of NF- κ B and STAT3 pathways. Activation of STAT3 signaling
364 has been strongly related to tumor initiation, development and progression, while levels of
365 activated STAT3 in the tissue correlate with tumor invasion, TNM stage and reduced overall
366 survival of CRC patients (45). In addition, the activation of epithelial STAT3 was reported to
367 downregulate the expression of chemokines important for the recruitment of Treg cells in the
368 intestine (24). Therefore, it is tempting to speculate that during *H. pylori* infection, activation of
369 STAT3 in intestinal and colonic epithelial cells contributes to loss of Treg recruitment, thereby
370 supporting malignant transformation of the intestinal tissue. This central role for STAT3
371 during carcinogenesis in the intestine is supported by the fact that depletion of STAT3 in
372 *Apc^{+/-min}* mice led to a reduction in the incidence of early adenomas (46). Importantly, we
373 observed a reduction and normalization of STAT3 levels after eradication of *H. pylori*, which
374 resulted in a normalization of tumor load. Notably, for eradication, a treatment regimen also
375 applied in humans was used in order to be able to translate the results to humans.

376 The function of STAT3 as oncogene or tumor suppressor seems to be determined by the
377 milieu eliciting its activation as well as the local gut microbiota (47), which is increasingly
378 recognized as an important regulator of colonic cancer development (48). Interestingly,
379 microbial induction of IL-17A production has been shown to endorse colon cancer initiation
380 and progression in *Apc^{+/-min}* mice, which was mediated via STAT3 signaling (49). We thus
381 hypothesized that alterations in microbiota compositions in the intestine and colon induced
382 by *H. pylori* may also contribute to carcinogenesis (29, 50). Indeed, when housing mice
383 under germ-free conditions, activation of STAT3 and tumor development were lower upon *H.*

384 *pylori* infection, but not completely normalized, indicating that microbiota alterations are
385 involved in the phenotype but not exclusively responsible.

386 Such disturbances in gut microbiota communities have been shown to contribute to CRC
387 development and progression (28). *H. pylori* is known to affect not only local gastric
388 microbiota, but also distant microbial populations in intestine and colon (29, 51). It has been
389 shown that inflammation-driven dysregulation of microbiota can promote colorectal tumor
390 formation and progression (52) and that in response to bacterial stimuli or pathogen
391 associated molecular receptors, pro-inflammatory pathways such as c-Jun/JNK and STAT3
392 signaling pathways are activated and accelerate intestinal tumor growth in *Apc*^{+/*min*} mice (47).
393 This was supported by our findings from transferring stool of *H. pylori*-infected SPF mice into
394 germ-free *Apc*^{+/*1638N*} mice, where we observed an accelerated tumor development in
395 comparison to stool transferred from non-infected mice. Together, these data indicate that *H.*
396 *pylori* induced microbial signatures are involved in and indispensable to promote intestinal
397 tumor growth.

398 Our data revealed a distinct mucus-degrading microbiota signature associated with *H. pylori*
399 infection in mice, namely enrichment with *Akkermansia spp.* and *Ruminococcus spp.*, while
400 in human samples from *H. pylori* infected patients, bacterial taxa associated with CRC,
401 Prevotellaceae and Peptostreptococcales, were found (28). Although some studies
402 established an inverse correlation between the presence of *Akkermansia* and gastrointestinal
403 diseases (53), *Akkermansia* has been reported to be increased in CRC patients most likely
404 due to the overexpression of certain mucins in the tumors (54). Notably, we also observed a
405 general loss of goblet cells, which are important to produce mucins and antimicrobial
406 peptides. This loss of goblet cells was also observed in clinical samples from *H. pylori*
407 infected patients undergoing colonoscopy. Thus, *H. pylori* infection disrupts, by two distinct
408 mechanisms, intestinal mucus integrity essential to maintain a healthy barrier to impair
409 bacterial penetration. In the absence of a sufficient regulatory T cell response – as observed
410 here -, which normally keeps inflammatory signals at bay, the carefully balanced
411 homeostasis maintained in the gut by the interplay of a “healthy” microbiome and an intact
412 mucosa then fails to balance the proinflammatory signature elicited by *H. pylori* infection,
413 enabling carcinogenesis. Eradication of *H. pylori* restored intestinal homeostasis with
414 reappearance of goblet cells and normalized the intestinal immune signature, which then
415 completely abrogated the tumor-promoting effect.

416 Importantly, when analyzing colonic biopsies from *H. pylori* infected patients, we could
417 observe the very same alterations as seen in mice, with activation of pro-carcinogenic
418 signaling pathways and a significant reduction in Treg cells, and an increase of CD3⁺ cells.
419 The attenuated phenotype in eradicated patients highlight the clinical relevance of our

420 findings and indicate, that *H. pylori* infection is more than a mere risk factor for colon
421 carcinogenesis, but actively promotes a procarcinogenic niche in the colon, that may be
422 prevented by eradication of *H. pylori*, which therefore could decrease the risk of CRC
423 development in infected individuals. However, studies showing a correlation between *H.*
424 *pylori* infection and CRC did not address the effect of antibiotic therapy. The inclusion of such
425 cohorts in future studies is important to determine the impact of *H. pylori* eradication in CRC
426 development.

427 In summary, our study not only provides solid experimental evidence that *H. pylori* infection
428 accelerates tumor development, but also offers insight into the underlying mechanisms and
429 suggests *H. pylori* screening and eradication as a potential measure for CRC prevention
430 strategies.

431
432

433 **ACKNOWLEDGEMENTS**

434 We thank members of the laboratory ‘Chronic inflammation and carcinogenesis’ for
435 experimental help as well as critical discussion, with special thanks to Maximilian Koch, Karin
436 Taxauer, Martin Skerhut and Teresa Burrell for experimental support. We thank Julia
437 Horstmann and the team of the ColoBac study at the Klinik und Poliklinik für Innere Medizin
438 II, Klinikum rechts der Isar, for the supply of human biopsies. We thank Core Facility
439 Mikrobiom of the ZIEL Institute for Food & Health, Technical University of Munich, for 16S
440 rRNA Sequencing services, as well as Dharmesh Singh and Nyssa Cullin. We thank Core
441 Facility Gnotobiology of the ZIEL Institute for Food & Health, Technical University of Munich,
442 for germ-free mice.

443 **FUNDING**

444 This work was funded by the Deutsche Forschungsgemeinschaft (DFG [German Research
445 Foundation]) SFB1371/1-395357507 (project P09).

446 **AUTHOR CONTRIBUTIONS**

447 A.R., R.M.L and M.G. conceived the study. A.R., A.D. and R.M.L. designed and analyzed
448 experiments. S.J. contributed and provided code and support to single cell RNA sequencing
449 and chip cytometry. V.E. and A.W. contributed to experiments. A.D., S.J, and R.M.L
450 contributed to data interpretation. M.V. and M.Q. provided human biopsies. K.P.J. provided
451 mouse models and critically revised the article. D.H., D.H.B. and L.D. critically revised the
452 article. A.R. and R.M.L. wrote the article. A.R., R.M.L. and M.G. revised the article. M.G.
453 acquired the funding. All authors read and reviewed the article.

454 **COMPETING INTERESTS**

455 The authors declare no competing interests.

456 **DATA AVAILABILITY**

457 Raw single cell RNA sequencing and 16S rRNA sequencing data are available under the
458 BioProject ID PRJNA808836.

459

460 MATERIALS AND METHODS

461

462 STUDY DESIGN

463 This study was conceptualized to investigate the underlying mechanisms of *H. pylori* induced
464 colorectal carcinogenesis.

465 Tumor mouse models $Apc^{+/min}$, initially obtained from Jackson Laboratories, and $Apc^{+/1638N}$
466 mice, provided by Prof. Klaus-Peter Janssen (Klinikum rechts der Isar, München) (41), were
467 bred under specific pathogen-free conditions at our animal facility at the Technical University
468 of Munich. Both female and male mice were used and co-housed with littermate controls.
469 $Apc^{+/1638N}$ mice and wild type littermates were re-derived germ-free from conventional mice
470 by Prof. Bleich and Dr. Basic (Hannover medical school, Hannover).

471 Female C57BL/6 mice were purchased from Envigo RMS GmbH at an age of 6 weeks and
472 acclimatized to our animal facility for 1-2 weeks prior infection. Mice were fed with a standard
473 diet and water ad libitum and maintained under a 12-hour light-dark cycle. DNA extracted
474 from mouse tails was used for genotyping. All animal experiments were conducted in
475 compliance with European guidelines for the care and use of laboratory animals and were
476 approved by the Bavarian Government (Regierung von Oberbayern, Az.55.2-1-54-2532-161-
477 2017).

478 87 fresh colonoscopy biopsies were collected within the framework of the COLOBAC study
479 of the CRC1371 (Dept. of Surgery and II. Medical Dept. Klinikum rechts der Isar, Technical
480 University of Munich, Germany). 67 FFPE colon biopsies were obtained from the Klinikum
481 Bayreuth. Both studies were approved by the respective ethics committees (Klinikum rechts
482 der Isar #322/18, Klinikum Bayreuth #241_20Bc).

483 *H. pylori* status of colonoscopy biopsies was determined in serum samples using the
484 recomwell Helicobacter IgG kit (Mikrogen) according to manufacturer's instructions. *H. pylori*
485 status of FFPE biopsies was determined histologically in corresponding gastric biopsies by
486 Prof. Michael Vieth.

487

488 RANDOMISATION AND BLINDING

489 Animals were randomly distributed to control/infection groups. The infection status of mice
490 was known to the investigating researcher. *H. pylori* status of patients was not known to the
491 researcher during sample analysis.

492

493 *H. PYLORI* INFECTION

494 *H. pylori* pre-mouse Sidney Strain 1 (PMSS1) was cultured on Wilkins-Chalgren (WC) Dent
495 (containing vancomycin, trimethoprim, cefsoludin and amphotericin) agar plates in a
496 microaerophilic atmosphere (5% O₂, 10% CO₂). 6–8-week old mice were orally gavaged

497 twice within 72 hours with 2×10^8 *H. pylori* PMSS1 in 200 μ l brain-heart-infusion (BHI)
498 medium containing 20% fetal calve serum (FCS). Infection status was determined by plating
499 homogenized stomach tissue on WC Dent plates supplemented with 200 g/ml bacitracin, 10
500 g/ml nalidixic acid and 3 g/ml polymycin B, and counting colony-forming units (CFU).

501

502 **H. PYLORI ERADICATION**

503 After 4 weeks of infection, *H. pylori* eradication was performed with an antibiotic cocktail
504 containing clarithromycin (Eberth) (7.15 mg/kg/day), metronidazole (Carl Roth) (14.2
505 mg/kg/day) and the proton-pump inhibitor omeprazole (Carl Roth) (400 μ mol/kg/day) by oral
506 gavage twice daily for 7 consecutive days . Omeprazole was dissolved in 200 μ l 2.5%
507 Hydroxy-propyl-methyl-cellulose (Sigma-Aldrich) with pH adjusted to 9. Antibiotics, dissolved
508 in 200 μ l PBS, were administered 45 minutes after omeprazole (30).

509

510 **STOOL TRANSFER**

511 SPF *Apc*^{+1638N} mice and wild type littermates were infected at an age of 6-8 weeks and after
512 24 weeks of infection, stool pellets were collected from these “donor” mice, dissolved in
513 0.1ml PBS/g stool and administered via oral gavage to germ-free *Apc*^{+1638N} “recipient” mice.

514

515 **HISTOLOGY AND IMMUNOHISTOCHEMISTRY**

516 Small intestine and colon were longitudinally opened and flushed with phosphate-buffered
517 saline (PBS). Solid neoplastic lesions were assessed and measured macroscopically by two
518 independent examiners. Dissected tissue was fixed in 4% formaldehyde, embedded in
519 paraffin and 4 μ m thick sections were used for staining. For immunohistochemical stainings,
520 antigen retrieval was achieved with 10 mM sodium citrate (pH 6) or 1 mM EDTA (pH 8), and
521 primary antibodies were applied overnight at 4°C (Table 1). Horseradish peroxidase (HRP)
522 coupled secondary antibodies (Promega) and diaminobenzidine (DAB) (CellSignaling) were
523 used to detect signal. Periodic acid Schiff (PAS) (Carl Roth) staining was performed to
524 assess the quantity of mucus producing goblet cells. Stomach, intestinal and colonic sections
525 were blindly quantified by two independent researchers by measuring the area of a functional
526 unit (stomach gland, intestinal crypt/villus unit or colonic crypt) and counting positive cells per
527 mm², using Aperio ImageScope (Leica BioSystems).

528

529 **Table 1. Antibodies used for immunohistochemical evaluation.**

Target	Clone	Origin/Target	Antigen retrieval	Dilution	Company
CD3	SP7	Rabbit mAB	sodium citrate	1:150	Thermo Fisher
Ki67	D3B5	Rabbit mAB	sodium citrate	1:400	Cell Signaling
pSTAT3	D3A7	Rabbit mAB	EDTA	1:200	Cell Signaling

530

532 **CHIPCYTOMETRY AND AUTOMATIC IMAGE QUANTIFICATION**

533 Murine intestinal and colonic cross-sections were preserved with O.C.T. compound (Tissue
534 Tek) in cryomolds (Tissue Tek) and kept frozen at -80°C. For ChipCytometry, 7µm thick
535 sections were cut on a Cryostat (Leica), fixed in Fixation Buffer (ZELLKRAFTWERK) for 45
536 minutes and subsequently transferred to CellSafe Chips (ZELLKRAFTWERK).
537 ChipCytometry on human FFPE biopsies was performed according to the procedure
538 described in Jarosch, Köhler et al (55). Briefly, tissue sections were rehydrated on coverslips
539 and antigen retrieval was performed using TRIS-EDTA buffer (pH 8.5) and then transferred
540 to CellSafe Chips (ZELLKRAFTWERK). Alternating cycles of staining, immunofluorescence
541 detection and photobleaching were performed for various markers (Table 2). Automated
542 image processing was performed as described in Jarosch, Köhler et al., which includes
543 segmentation of cells, removing of outliers and spatial spill over correction (55). The resulting
544 cell – marker matrix was analyzed using FlowJo software (V10.8.0), which enabled absolute
545 quantification of cells.

546

547 **Table 2. Antibodies used for ChipCytometry.**

Epitope	Fluorochrome	Clone	Dilution	Company	Catalog #
anti-mouse CD3	PerCP/Cy5.5	17A2	1:200	BioLegend	100218
anti-mouse CD4	eFluor450	RM4-5	1:80	BioLegend	100531
anti-mouse CD45	FITC	30-F11	1:100	BioLegend	103108
anti-mouse Foxp3	PE	FJK-16s	1:80	eBioscience	14-5773-82
Pan-cytokeratin	AlexaFluor 488	C-11	1:100	BioLegend	628602
Hoechst	BUV395	-	1:50.000	ThermoScientific	H3570
α-SMA	eFluor570	1A4	1:750	eBioscience	41-9760-80
anti-human CD3	unconjugated	SP7	1:150	ThermoScientific	RM-9107-S1
anti-human CD4	AlexaFluor 488	polyclonal	1:50	R&D Systems	FAB8165G
anti-human CD45	PerCP/Cy5.5	HI30	1:80	BioLegend	304028
anti-human Foxp3	PE	236A/E7	1:30	eBioscience	563791
2 nd anti-rabbit	PE	Polyclonal	1:300	BioLegend	406421

548

549 **LAMINA PROPRIA AND INTRAEPITHELIAL LYMPHOCYTE ISOLATION AND** 550 **FLOW CYTOMETRY**

551 Harvested intestinal tissue was cut open longitudinally after removing Peyer's Patches and
552 adjacent tissue. Subsequently, tissue was treated with 30mM EDTA, filtered supernatants
553 were collected as intraepithelial lymphocytes and remaining tissue was digested with
554 0.5mg/mL collagenase from Clostridium histolyticum Type IV (Sigma Aldrich) and 10µg/mL
555 DNase I (Applichem). Filtered and centrifuged lamina propria cell suspensions were density
556 separated using a Percoll gradient (Thermo Fisher).

557 Fresh human biopsies were collected in Hank's Balanced Salt Solution w/o Mg²⁺/Ca²⁺
 558 (HBSS) and digested with 0.1% collagenase from Clostridium histolyticum Type IV (Sigma
 559 Aldrich) for 30 min. at 37°C. Digestion was stopped by adding 20 mL HBSS and
 560 centrifugation twice. Isolated lymphocytes were frozen in Dimethyl sulfoxide (Applichem) +
 561 20 % FCS at -80° C.

562 Single cell suspensions were blocked with anti-mouse CD16/CD32 or anti human TruStain
 563 FcX and live/dead staining performed with Zombie Aqua (BioLegend) in PBS. Surface
 564 antibodies (Table 3) were diluted according to titration experiments and cells stained for 30
 565 min at 4° C. For transcription factors, Foxp3 Transcription Factor Staining Buffer Set
 566 (eBioscience) was used according to manufacturer's instructions. For stimulation with whole
 567 *H. pylori* lysate, cells were stimulated for 12 hours with 20µg/mL PMSS1 lysate at 37° C and
 568 protein transport inhibitor Golgi Plug (BD Biosciences) added 1:1000 after 7 hours for a total
 569 of 5 hours. Stimulated cells were stained with intracellular cytokine staining kit according
 570 manufacturer's instructions (BD Biosciences). Stained single cell suspensions were acquired
 571 on a CytoFlex S (Beckman Coulter) and analyzed using FlowJo software (V10.8.0).

572

573 **Table 3. Antibodies used for flow cytometry.**

Epitope	Fluorochrome	Clone	Dilution	Catalog #	Company
anti-mouse CD16/CD32	-	93	1:500	14-0161-86	eBioscience
anti-mouse CD45	AlexaFluor 700	30-F11	1:400	103128	BioLegend
anti-mouse CD3ε	FITC	500A2	1:200	152304	BioLegend
anit-mouse CD4	BV605	RM4-5	1:250	100548	BioLegend
anti-mouse CD4	eFluor450	RM4-5	1:250	48-0042-82	eBioscience
anti-mouse CD8a	APC-H7	53.6-7	1:250	560182	BD Biosciences
anti-mouse FoxP3	eFluor450	FJKL-16s	1:200	45-5773-82	eBioscience
anti-mouse IL-17A	APC	eBio17B7	1:150	17-7177-81	eBioscience
anti-human CD45	AlexaFluor 700	2D1	1:50	368514	BioLegend
anti-human CD3	FITC	OKT3	1:300	317306	BioLegend
anti-human CD4	PB450	SK3	1:30	344620	BioLegend
anti-human CD8	APC-H7	SK1 (RUO)	1:150	560179	BD Biosciences
anti-human FoxP3	PerCP/Cy5.5	PCH101		35-4776-42	eBioscience
Human TruStain FcX	-	-	1:500	422302	BioLegend

574

575 SINGLE CELL RNA SEQUENCING

576 Intestinal and colonic tissue was harvested and cells were isolated as described in section
 577 "Lymphocyte isolation and Flow cytometry". Single cell suspensions were stained with anti-
 578 mouse CD45 PB450 (Clone: 30-F11, BioLegend, #103126), anti-mouse EPCAM APC
 579 (Clone: G8.8, BioLegend, #118214) and Propidium Iodide (PI). CD45+ PI- and EPCAM+ PI-
 580 cells were sorted.

581 For cell hashing TotalSeq-B anti-mouse Hashtags 1, 2 and 5 to 8 (M1/42; 30-F11, Biolegend,
582 155831, 155833, 155839, 155841, 155843, 155845) were used at a dilution of 1:50.

583 Single cell RNA Sequencing was performed with 10X Genomics, according to manufacturer's
584 instructions (Chromium™ Single Cell 3' GEM v3 kit). Sorted cells were centrifuged and
585 resuspended in mastermix and 37.8 µl of water, before 70 µl of the cell suspension was
586 transferred to the chip. QC was performed with a high sensitivity DNA Kit (Agilent) on
587 a Bioanalyzer 2100, and libraries were quantified with the Qubit dsDNA HS assay kit (life
588 technologies).

589 Libraries were pooled according to their minimal required read counts (20.000 reads/cell for
590 gene expression libraries). Illumina paired end sequencing was performed with 150 cycles on
591 a NovaSeq 6000.

592 Annotation was performed using cellranger (V5.0.0, 10X genomics) against
593 the murine reference genome GRCm38 (mm10-2020-A). All subsequent analysis was
594 performed using SCANPY V1.6 (56). Preprocessing was performed following the guidelines
595 of best practice in single-cell RNA-seq analysis (57) and involved less than 15%
596 mitochondrial genes, regressing out cell cycle, mitochondrial genes and total counts. The
597 data was normalized per cell count and logarithmized. Genes used for gene scores are listed
598 in Table S1 and the scores were computed with the SCANPY build in function
599 "sc.tl.score_genes".

600 RNA velocities were calculated using velocityto (18) and analyzed with scVelo (V 0.2.3) (58).

601

602 **16S RRNA SEQUENCING**

603 Bacterial DNA extraction and 16S rRNA sequencing was either performed as described
604 previously (59, 60) by the Core Facility Microbiome of the ZIEL Institute for Food & Health
605 (Technical University of Munich) or as follows: small intestine and colon tissue were
606 homogenized with a Precellys® 24 homogeniser (Avantor). Phenol chloroform DNA isolation
607 and ethanol precipitation were performed following modified protocols of P.J. Turnbaugh et
608 al., 2009 and E. G. Zoetendal et al. 2006 (61, 62). Subsequently, the V3/V4 region of
609 the 16S rRNA gene was amplified and double indexed using barcoding primers modeled
610 after Kozich *et al.* PCR fragments were purified using magnetic AMPure XP beads (Beckman
611 Coulter, USA) according to manufacturer's instructions (63). The final pooled library
612 was sequenced on an Illumina MiSeq with Reagent Kit v3 (Illumina) for 600 cycles of paired-
613 end reads.

614 Raw sequences were analyzed using the Qiime2 platform (v2021.4) (64). In detail,
615 denoising, removing of chimeras and generation of Amplicon Sequence Variants (ASVs) was
616 performed with dada2. Subsequently, a phylogenetic tree was generated and diversity
617 measures were calculated. Chao1 index was used to determine community alpha diversity.

618 Taxonomic classification was performed with a qiime2 feature classifier trained on the
619 SILVA132 99% OTUs, specifically targeting the V3 region. Linear discriminant analysis effect
620 size (LEfSe) determining differentially abundant features was performed on the online
621 interface at <http://huttenhower.sph.harvard.edu/lefse/>, developed by Segata et al. (65).

622

623 **QUANTITATIVE PCR**

624 Stomach, small intestine and colon tissue were homogenized with Precellys® 24
625 homogeniser (Avantor) and RNA isolation was performed with a Maxwell 48 RSC simply
626 RNA Tissue Kit on a Maxwell RSC Instrument (Promega). cDNA was synthesized with
627 Moloney Murine Leukemia Virus Reverse Transcriptase RNase H- Point Mutant (Promega).
628 Gene expression was assessed with GoTaq qPCR Mastermix (Promega) on a CFX384
629 system (Bio-Rad). The quantitative PCR consisted of 40 cycles of amplification with 15 sec
630 denaturation at 95 °C, 1 min annealing and amplification at 60 °C. According to the $\Delta\Delta CT$
631 method, CT values were normalized to *Gapdh* and to uninfected controls, in order to
632 determine fold changes in gene expression. The sequences of primers used are summarized
633 in Table 3.

634

635 **Table 3. Primer sequences used for qPCR.**

Gene	Forward sequence	Reverse sequence
<i>Gapdh</i>	GCCTTCTCCATGGTGGTGAA	GCACAGTCAAGGCCGAGAAT
<i>Foxp3</i>	AGGAGCCGCAAGCTAAAAGC	TGCCTTCGTGCCCACTGT

636

637 **STATISTICAL ANALYSIS**

638 Statistical analysis was conducted on biological replicates as stated in the Fig. legends.
639 Depending on Gaussian distribution, statistical significance between two groups was
640 determined with unpaired student's t-test or Mann-Whitney-U test and for analysis among
641 more than two groups, one-way ANOVA with Tukey's multiple-comparisons test or Kruskal-
642 Wallis-test with Dunn's multiple-comparisons test. P values below 0.05 were considered
643 significant. Exact p values are stated when relevant. Statistical analysis was carried out using
644 Prism 8 (GraphPad Software).

645

646

647

648 REFERENCES

- 649 1. Shi Y, Liu XF, Zhuang Y, Zhang JY, Liu T, Yin Z, et al. Helicobacter pylori-induced
650 Th17 responses modulate Th1 cell responses, benefit bacterial growth, and contribute to
651 pathology in mice. *J Immunol.* 2010;184(9):5121-9.
- 652 2. Nagai S, Mimuro H, Yamada T, Baba Y, Moro K, Nochi T, et al. Role of Peyer's
653 patches in the induction of Helicobacter pylori-induced gastritis. *Proc Natl Acad Sci U S A.*
654 2007;104(21):8971-6.
- 655 3. Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, et al. cag, a
656 pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated
657 virulence factors. *Proceedings of the National Academy of Sciences of the United States of*
658 *America.* 1996;93(25):14648-53.
- 659 4. Stein M, Rappuoli R, Covacci A. Tyrosine phosphorylation of the Helicobacter pylori
660 CagA antigen after cag-driven host cell translocation. *Proc Natl Acad Sci U S A.*
661 2000;97(3):1263-8.
- 662 5. Mejias-Luque R, Zoller J, Anderl F, Loew-Gil E, Vieth M, Adler T, et al. Lymphotoxin
663 beta receptor signalling executes Helicobacter pylori-driven gastric inflammation in a T4SS-
664 dependent manner. *Gut.* 2017;66(8):1369-81.
- 665 6. Oertli M, Sundquist M, Hitzler I, Engler DB, Arnold IC, Reuter S, et al. DC-derived IL-
666 18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and
667 asthma protection. *J Clin Invest.* 2012;122(3):1082-96.
- 668 7. Kaebisch R, Mejias-Luque R, Prinz C, Gerhard M. Helicobacter pylori cytotoxin-
669 associated gene A impairs human dendritic cell maturation and function through IL-10-
670 mediated activation of STAT3. *J Immunol.* 2014;192(1):316-23.
- 671 8. Kao JY, Zhang M, Miller MJ, Mills JC, Wang B, Liu M, et al. Helicobacter pylori
672 immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in
673 mice. *Gastroenterology.* 2010;138(3):1046-54.
- 674 9. Oertli M, Noben M, Engler DB, Semper RP, Reuter S, Maxeiner J, et al. Helicobacter
675 pylori gamma-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence
676 and immune tolerance. *Proc Natl Acad Sci U S A.* 2013;110(8):3047-52.
- 677 10. Chen CC, Liou JM, Lee YC, Hong TC, El-Omar EM, Wu MS. The interplay between
678 Helicobacter pylori and gastrointestinal microbiota. *Gut Microbes.* 2021;13(1):1-22.
- 679 11. Lofgren JL, Whary MT, Ge Z, Muthupalani S, Taylor NS, Mobley M, et al. Lack of
680 commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays
681 intraepithelial neoplasia. *Gastroenterology.* 2011;140(1):210-20.
- 682 12. Gravina AG, Zagari RM, De Musis C, Romano L, Loguercio C, Romano M.
683 Helicobacter pylori and extragastric diseases: A review. *World J Gastroenterol.*
684 2018;24(29):3204-21.
- 685 13. Zuo Y, Jing Z, Bie M, Xu C, Hao X, Wang B. Association between Helicobacter pylori
686 infection and the risk of colorectal cancer: A systematic review and meta-analysis. *Medicine*
687 *(Baltimore).* 2020;99(37):e21832.
- 688 14. Becht E, McInnes L, Healy J, Dutertre CA, Kwok IWH, Ng LG, et al. Dimensionality
689 reduction for visualizing single-cell data using UMAP. *Nat Biotechnol.* 2018.
- 690 15. Osman A, Yan B, Li Y, Pavelko KD, Quandt J, Saadalla A, et al. TCF-1 controls Treg
691 cell functions that regulate inflammation, CD8(+) T cell cytotoxicity and severity of colon
692 cancer. *Nat Immunol.* 2021;22(9):1152-62.
- 693 16. Miragaia RJ, Gomes T, Chomka A, Jardine L, Riedel A, Hegazy AN, et al. Single-Cell
694 Transcriptomics of Regulatory T Cells Reveals Trajectories of Tissue Adaptation. *Immunity.*
695 2019;50(2):493-504 e7.
- 696 17. Vasanthakumar A, Liao Y, Teh P, Pascutti MF, Oja AE, Garnham AL, et al. The TNF
697 Receptor Superfamily-NF-kappaB Axis Is Critical to Maintain Effector Regulatory T Cells in
698 Lymphoid and Non-lymphoid Tissues. *Cell Rep.* 2017;20(12):2906-20.
- 699 18. La Manno G, Soldatov R, Zeisel A, Braun E, Hochgerner H, Petukhov V, et al. RNA
700 velocity of single cells. *Nature.* 2018;560(7719):494-8.
- 701 19. Parikh K, Antanaviciute A, Fawcner-Corbett D, Jagielowicz M, Aulicino A, Lagerholm
702 C, et al. Colonic epithelial cell diversity in health and inflammatory bowel disease. *Nature.*
703 2019;567(7746):49-55.

- 704 20. Moor AE, Harnik Y, Ben-Moshe S, Massasa EE, Rozenberg M, Eilam R, et al. Spatial
705 Reconstruction of Single Enterocytes Uncovers Broad Zonation along the Intestinal Villus
706 Axis. *Cell*. 2018;175(4):1156-67 e15.
- 707 21. Brandt S, Kwok T, Hartig R, Konig W, Backert S. NF-kappaB activation and
708 potentiation of proinflammatory responses by the *Helicobacter pylori* CagA protein. *Proc Natl*
709 *Acad Sci U S A*. 2005;102(26):9300-5.
- 710 22. Menheniott TR, Judd LM, Giraud AS. STAT3: a critical component in the response to
711 *Helicobacter pylori* infection. *Cell Microbiol*. 2015;17(11):1570-82.
- 712 23. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, et al.
713 gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle
714 progression during colitis-associated tumorigenesis. *Cancer cell*. 2009;15(2):91-102.
- 715 24. Nguyen AV, Wu YY, Liu Q, Wang D, Nguyen S, Loh R, et al. STAT3 in epithelial cells
716 regulates inflammation and tumor progression to malignant state in colon. *Neoplasia*.
717 2013;15(9):998-1008.
- 718 25. Asada R, Saito A, Kawasaki N, Kanemoto S, Iwamoto H, Oki M, et al. The
719 endoplasmic reticulum stress transducer OASIS is involved in the terminal differentiation of
720 goblet cells in the large intestine. *J Biol Chem*. 2012;287(11):8144-53.
- 721 26. Aden K, Rehman A, Falk-Paulsen M, Secher T, Kuiper J, Tran F, et al. Epithelial IL-
722 23R Signaling Licenses Protective IL-22 Responses in Intestinal Inflammation. *Cell Rep*.
723 2016;16(8):2208-18.
- 724 27. Katoh M, Katoh M. Notch signaling in gastrointestinal tract (review). *Int J Oncol*.
725 2007;30(1):247-51.
- 726 28. Wirbel J, Pyl PT, Kartal E, Zych K, Kashani A, Milanese A, et al. Meta-analysis of
727 fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer.
728 *Nat Med*. 2019;25(4):679-89.
- 729 29. Guo Y, Zhang Y, Gerhard M, Gao JJ, Mejias-Luque R, Zhang L, et al. Effect of
730 *Helicobacter pylori* on gastrointestinal microbiota: a population-based study in Linq, a high-
731 risk area of gastric cancer. *Gut*. 2020;69(9):1598-607.
- 732 30. van Zanten SJ, Kolesnikow T, Leung V, O'Rourke JL, Lee A. Gastric transitional
733 zones, areas where *Helicobacter* treatment fails: results of a treatment trial using the Sydney
734 strain mouse model. *Antimicrob Agents Chemother*. 2003;47(7):2249-55.
- 735 31. Franceschi F, Covino M, Roubaud Baudron C. Review: *Helicobacter pylori* and
736 extragastric diseases. *Helicobacter*. 2019;24 Suppl 1:e12636.
- 737 32. Kim TJ, Kim ER, Chang DK, Kim YH, Baek SY, Kim K, et al. *Helicobacter pylori*
738 infection is an independent risk factor of early and advanced colorectal neoplasm.
739 *Helicobacter*. 2017;22(3).
- 740 33. Arnold IC, Dehzad N, Reuter S, Martin H, Becher B, Taube C, et al. *Helicobacter*
741 *pylori* infection prevents allergic asthma in mouse models through the induction of regulatory
742 T cells. *J Clin Invest*. 2011;121(8):3088-93.
- 743 34. Caruso R, Fina D, Paoluzi OA, Del Vecchio Blanco G, Stolfi C, Rizzo A, et al. IL-23-
744 mediated regulation of IL-17 production in *Helicobacter pylori*-infected gastric mucosa. *Eur J*
745 *Immunol*. 2008;38(2):470-8.
- 746 35. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical
747 impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in
748 patients with colorectal cancer. *Cancer Res*. 2011;71(4):1263-71.
- 749 36. Du R, Zhao H, Yan F, Li H. IL-17+Foxp3+ T cells: an intermediate differentiation
750 stage between Th17 cells and regulatory T cells. *J Leukoc Biol*. 2014;96(1):39-48.
- 751 37. Ma C, Dong X. Colorectal cancer-derived Foxp3(+) IL-17(+) T cells suppress tumour-
752 specific CD8+ T cells. *Scand J Immunol*. 2011;74(1):47-51.
- 753 38. Yang S, Wang B, Guan C, Wu B, Cai C, Wang M, et al. Foxp3+IL-17+ T cells
754 promote development of cancer-initiating cells in colorectal cancer. *J Leukoc Biol*.
755 2011;89(1):85-91.
- 756 39. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ.
757 Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of
758 human colon carcinoma. *Gastroenterology*. 2009;137(4):1270-9.

- 759 40. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, et al. Mutations in
760 APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer. *Proc Natl Acad*
761 *Sci U S A*. 2002;99(14):9433-8.
- 762 41. Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, et al. APC and
763 oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and
764 progression. *Gastroenterology*. 2006;131(4):1096-109.
- 765 42. Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Goktuna SI, Ziegler PK, et al.
766 Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like
767 properties. *Cell*. 2013;152(1-2):25-38.
- 768 43. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis:
769 a meta-analysis. *Gut*. 2001;48(4):526-35.
- 770 44. Waldner MJ, Neurath MF. Mechanisms of Immune Signaling in Colitis-Associated
771 Cancer. *Cell Mol Gastroenterol Hepatol*. 2015;1(1):6-16.
- 772 45. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K, et al.
773 Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. *Oncol Rep*.
774 2006;15(6):1445-51.
- 775 46. Musteanu M, Blaas L, Mair M, Schleder M, Bilban M, Tauber S, et al. Stat3 is a
776 negative regulator of intestinal tumor progression in *Apc(Min)* mice. *Gastroenterology*.
777 2010;138(3):1003-11 e1-5.
- 778 47. Li Y, Kundu P, Seow SW, de Matos CT, Aronsson L, Chin KC, et al. Gut microbiota
779 accelerate tumor growth via c-jun and STAT3 phosphorylation in *APCMin/+* mice.
780 *Carcinogenesis*. 2012;33(6):1231-8.
- 781 48. Compare D, Nardone G. Contribution of gut microbiota to colonic and extracolonic
782 cancer development. *Dig Dis*. 2011;29(6):554-61.
- 783 49. Wick EC, Rabizadeh S, Albesiano E, Wu X, Wu S, Chan J, et al. Stat3 activation in
784 murine colitis induced by enterotoxigenic *Bacteroides fragilis*. *Inflamm Bowel Dis*.
785 2014;20(5):821-34.
- 786 50. Iino C, Shimoyama T. Impact of *Helicobacter pylori* infection on gut microbiota. *World*
787 *J Gastroenterol*. 2021;27(37):6224-30.
- 788 51. Kienesberger S, Cox LM, Livanos A, Zhang XS, Chung J, Perez-Perez GI, et al.
789 Gastric *Helicobacter pylori* Infection Affects Local and Distant Microbial Populations and Host
790 Responses. *Cell reports*. 2016;14(6):1395-407.
- 791 52. Uronis JM, Muhlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. Modulation
792 of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. *PLoS*
793 *One*. 2009;4(6):e6026.
- 794 53. Wang L, Tang L, Feng Y, Zhao S, Han M, Zhang C, et al. A purified membrane
795 protein from *Akkermansia muciniphila* or the pasteurised bacterium blunts colitis associated
796 tumorigenesis by modulation of CD8(+) T cells in mice. *Gut*. 2020;69(11):1988-97.
- 797 54. Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP. Stool
798 microbiome and metabolome differences between colorectal cancer patients and healthy
799 adults. *PLoS One*. 2013;8(8):e70803.
- 800 55. Jarosch S, Köhlen J, Sarker RSJ, Steiger K, Janssen KP, Christians A, et al.
801 Multiplexed imaging and automated signal quantification in formalin-fixed paraffin-embedded
802 tissues by ChipCytometry. *Cell Reports Methods*. 2021;1(7).
- 803 56. Wolf FA, Angerer P, Theis FJ. SCANPY: large-scale single-cell gene expression data
804 analysis. *Genome Biol*. 2018;19(1):15.
- 805 57. Luecken MD, Theis FJ. Current best practices in single-cell RNA-seq analysis: a
806 tutorial. *Mol Syst Biol*. 2019;15(6):e8746.
- 807 58. Bergen V, Lange M, Peidli S, Wolf FA, Theis FJ. Generalizing RNA velocity to
808 transient cell states through dynamical modeling. *Nat Biotechnol*. 2020;38(12):1408-14.
- 809 59. Reitmeier S, Kiessling S, Neuhaus K, Haller D. Comparing Circadian Rhythmicity in
810 the Human Gut Microbiome. *STAR Protoc*. 2020;1(3):100148.
- 811 60. Reitmeier S, Kiessling S, Clavel T, List M, Almeida EL, Ghosh TS, et al. Arrhythmic
812 Gut Microbiome Signatures Predict Risk of Type 2 Diabetes. *Cell Host Microbe*.
813 2020;28(2):258-72 e6.

- 814 61. Zoetendal EG, Heilig HG, Klaassens ES, Boonjink CC, Kleerebezem M, Smidt H, et al.
815 Isolation of DNA from bacterial samples of the human gastrointestinal tract. *Nat Protoc.*
816 2006;1(2):870-3.
- 817 62. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A
818 core gut microbiome in obese and lean twins. *Nature.* 2009;457(7228):480-4.
- 819 63. Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a
820 dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data
821 on the MiSeq Illumina sequencing platform. *Appl Environ Microbiol.* 2013;79(17):5112-20.
- 822 64. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al.
823 Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2.
824 *Nat Biotechnol.* 2019;37(8):852-7.
- 825 65. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al.
826 Metagenomic biomarker discovery and explanation. *Genome Biol.* 2011;12(6):R60.
- 827




Fig. 1: *H. pylori* promotes intestinal carcinogenesis in *Apc* mouse models

(A) Kaplan-Meier survival curve comparing *H. pylori* infected and non-infected $Apc^{+/min}$ mice.

(B) Tumor counts of *H. pylori* infected ($n=18$) and non-infected ($n=10$) $Apc^{+/min}$ mice in small intestine and colon.

(C) Representative pictures of tumors (arrows) in the small intestine and colon of *H. pylori* infected and non-infected (Cont.) $Apc^{+/min}$ mice.

Each symbol represents one animal, from 3 independent, pooled experiments. Bars denote median. Statistical significance was determined with Mann-Whitney-U test or unpaired t-test, * $p < 0.05$.




Fig. 2: *H. pylori* infection induces a pro-inflammatory response in the intestine

(A) Representative pictures of colonic CD3+ stainings of *H. pylori* infected and non-infected *Apc*^{+/-min} mice after 12 weeks of infection are shown. White scale bars correspond to 200 μm , black scale bars to 20 μm . Quantification of positive cells per mm^2 small intestine and colon tissue is shown. Pooled data of 3 independent experiments.

(B) Flow cytometric analysis of intestinal lamina propria lymphocytes isolated from *H. pylori* infected and non-infected *Apc*^{+/-min} mice after 12 weeks of infection. Frequency of FoxP3+ positive cells of CD4+ T-cells are shown, gated on live, single cells, CD45+ and CD3+. Pooled data of 2 independent experiments.

(C) Representative CD3+ staining of stomach, small intestine and colon tissue sections of *H. pylori* infected and non-infected C57BL/6 mice after 24 weeks of infection. Quantification of intraepithelial cells per mm^2 is shown. White scale bars correspond to 200 μm , black scale bars to 20 μm . Pooled data of two independent experiments.

(D) Frequency of FoxP3 positive cells of CD4+ T-cells are shown. Cells were gated on live, single cells, CD45+ and CD3+. Pooled data of 2 independent experiments.

(E) Overview of colon tissue stained with multiplexed chip cytometry. Automatic image processing of multiplexed chip cytometry on colon tissue determines CD4+ T-cell properties in *H. pylori* positive and negative C57BL/6 mice. Frequencies of conventional T-cells (Tconv), regulatory T-cells (Treg) and intraepithelial regulatory T-cells (IE Treg) are shown. Scale bar in overview corresponds to 500 μm . Representative picture of colon tissue stained with multiplexed chip cytometry. FoxP3+ cell, defined by intranuclear FoxP3+, CD4+ CD3+ and CD45+ staining. Large scale bar corresponds to 100 μm , small scale bars to 10 μm . Representative data of one experiment.

(F) Annotated immune cells plotted as UMAP, clusters for further analysis are highlighted (1=CD4 Treg, 2=CD8 and CD8 TRM).

(G) Unsupervised clustering and annotation of Treg cluster as UMAP, n=217 cells. activated Tregs = act. Tregs, pTregs =peripherally induced Tregs, tTregs = thymically derived Tregs.

(H) Gene set score of Treg effector genes and Th17 differentiation genes, comparing activated Treg cells from small intestine and colon of *H. pylori* infected and non-infected *Apc*^{+/-min} (APC) mice. Statistical significance was determined with Kruskal-Wallis test.

Each symbol represents one animal/single cell, pooled from at least 2 independent experiments (n=6-10 mice/group/experiment) or 2 mice/group for single-cell data. Bars denote median. Unless otherwise specified, statistical significance was determined with student's t-test in case of normal distribution, otherwise by Mann-Whitney U test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.




Fig. 3: Activation of carcinogenic signaling pathways and loss of goblet cells characterize the intestinal epithelial response to *H. pylori* infection

(A) Annotated epithelial cells after unsupervised clustering plotted in UMAP space, n=2 mice per group, n= 4249 cells. Clusters for further analysis are highlighted (1= Enterocytes)

(B) Gene set score of STAT3 signaling genes, comparing intestinal enterocytes from *H. pylori* infected and non-infected *Apc*^{+/+} (WT) and *Apc*^{+/-min} (APC) mice. Statistical significance was determined with Kruskal-Wallis test.

(C) Representative pSTAT3, Ki67 and PAS staining of small intestine and colon tissue of *H. pylori*-infected and non-infected C57BL/6 mice. Quantification of positive cells per mm² is shown. White scale bars correspond to 200 μm, black scale bars to 20 μm. Pooled data of 2 independent experiments.

(D) Representative pictures of colonic pSTAT3 staining of *H. pylori* infected and non-infected *Apc*^{+/-min} and *Apc*^{+/-1638N} mice are shown. White scale bars correspond to 200 μm, black scale bars to 20 μm. Quantification of positive cells per mm² are shown. Pooled data of 3 independent experiments.

(E) Representative pictures of colonic PAS staining of *H. pylori* infected and non-infected *Apc*^{+/-min} and *Apc*^{+/-1638N} mice are shown. White scale bars correspond to 200 μm, black scale bars to 20 μm. Quantification of positive cells per mm² are shown. Pooled data of 3 independent experiments.

Each symbol represents one animal/single cell, pooled from at least 2 independent experiments (n=6-10 mice/group/experiment) or 2 mice/group for single-cell data. Bars denote median. Unless otherwise specified, statistical significance was determined with student's t-test in case of normal distribution, otherwise by Mann-Whitney U test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.




Fig. 4: *H. pylori* infection favors the presence of mucus-degrading microbiota

(A) Relative taxonomic frequencies on phyla level in 16S rRNA sequenced caecum and colon samples of *H. pylori* infected and non-infected C57BL/6 mice (n=6-8mice/group).

(B) Feature counts (ASVs) of *Akkermansia* spp. and *Ruminococcus* spp. in caecum, stool, small intestine and colon of *H. pylori* infected and non-infected C57BL/6 mice (n=6-8mice/group).

(C) Feature counts (ASVs) of *Ruminococcus* spp. of caecum, stool, small intestine and colon of *H. pylori* infected and non-infected *Apc*^{+/*min*} mice (n=4-5mice/group).

(D) Feature counts (ASVs) of *Akkermansia* spp. of caecum, stool, small intestine and colon of *H. pylori* infected and non-infected *Apc*^{+/*1638N*} mice (n=4-5mice/group).

Data of one representative experiment of 2-3 independent experiments, shown as bars with mean and standard deviation (SD). Statistical significance was determined with Mann-Whitney U test, **p < 0.01, ***p < 0.001.




Fig. 5: *H. pylori* induced intestinal carcinogenesis is prevented by eradication

- (A) Quantification of small intestinal and colonic intraepithelial CD3+ cells per mm² of *H. pylori* infected and non-infected germ-free *Apc*^{+/-1638N} mice is shown. Pooled data of two independent experiments (n= 8 mice/group).
- (B) Frequencies of FoxP3+ cells of CD4+ T-cells, gated on live, single cells, CD45+ and CD3+ of *H. pylori* infected and non-infected germ-free *Apc*^{+/-1638N} mice are included. Representative pseudocolor plots are shown. Pooled data of two independent experiments (n= 8 mice/group).
- (C) Quantification of intestinal intraepithelial pSTAT3+ cells per mm² of *H. pylori* infected and non-infected germ-free *Apc*^{+/-1638N} mice is shown. Pooled data of two independent experiments (n= 8 mice/group).
- (D) Quantification of intestinal and colonic PAS+ cells per mm² of *H. pylori* infected and non-infected germ-free *Apc*^{+/-1638N} mice is shown. Pooled data of two independent experiments (n= 8 mice/group).
- (E) Intestinal tumor counts of *H. pylori* infected and non-infected germ-free *Apc*^{+/-1638N} mice and representative pictures of tumors (circled) are shown (n=8 mice/group).
- (F) Intestinal tumor counts of stool transfer experiments from non-infected and *H. pylori* infected *Apc*^{+/-} or *Apc*^{+/-1638N} mice, respectively, (stool donors) into germ-free *Apc*^{+/-1638N} mice (stool recipients) are shown. Data of one experiment (n=2-4 mice/group).
- (G) Experimental setup of *H. pylori* eradication therapy of C57BL/6 and *Apc*^{+/-1638N} mice.
- (H) Tumor counts of non-infected, antibiotically treated, *H. pylori* infected and *H. pylori* eradicated *Apc*^{+/-1638N} mice and representative pictures of tumors in the small intestine. Data of one experiment (n= 2-3 mice/group).
- (I) Representative pictures of CD3+ stainings from small intestinal tissue of *H. pylori* infected and eradicated C57BL/6 mice are shown. White scale bars correspond to 200 μm, black scale bars to 20 μm. Quantification of positive cells per mm² is shown. Data of one experiment (n= 5-6 mice/group).
- (J) Flow cytometric analysis of intestinal lamina propria lymphocytes reveals frequency of FoxP3+ CD4+ T-cells, gated on live, single cells, CD45+ and CD3+. Data of one experiment (n= 5-6 mice/group).
- (K) Flow cytometric analysis of intestinal lamina propria lymphocytes reveals IL-17A release of CD4+ T-cells, restimulated with whole *H. pylori* lysate. Cells are gated on live, single cells, CD45+ and CD3+. Data of one experiment (n= 5-6 mice/group).
- (L) Representative pictures of pSTAT3 and PAS staining from intestinal tissue of *H. pylori* infected and eradicated C57BL/6 mice are shown. White scale bars correspond to 200 μm, black scale bars to 20 μm. Quantification of positive cells per mm² is shown. Data of one experiment (n= 5-6 mice/group).
- Each symbol represents one animal. Bars denote median. Statistical significance between two groups was determined with student's t-test in case of normal distribution and otherwise with Mann-Whitney U test. Among more than 2 groups, ordinary one-way ANOVA with Tukey's multiple comparisons test was applied in case of normal distribution, otherwise Kruskal-Wallis-Test with Dunn's multiple comparisons test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.




Fig. 6: *H. pylori* alters colonic homeostasis in human

(A) Representative HE, CD3+, pSTAT3 and PAS pictures of colonic tissue from *H. pylori* currently infected, eradicated and non-infected patients are shown. White scale bars correspond to 200 μ m, black scale bars to 20 μ m. Quantification of total CD3+, intraepithelial STAT3 and PAS positive cells per mm^2 are shown.

(B) Representative pictures of human colon tissue stained by multiplexed chip cytometry. FoxP3+ cell, defined by intranuclear FoxP3+, CD4+, CD3+ and CD45+ staining are shown for *H. pylori* negative and positive tissue. Large scale bar corresponds to 100 μ m, small scale bar to 10 μ m. Automatic image processing of multiplexed chip cytometry on colon tissue determines CD4+ T-cell properties in *H. pylori* positive and negative individuals: frequencies of conventional T-cells (Tconv), regulatory T-cells (Treg) and intraepithelial regulatory T-cells (IE Treg) are shown.

(C) Flow cytometric analysis of colon biopsies from *H. pylori* currently infected, eradicated and non-infected patients were conducted. Frequencies of FoxP3+ cells of CD4+ T-cells, gated on live, single cells, CD45+ and CD3+ are shown and representative pseudocolor plots of *H. pylori* currently infected and negative individuals are included.

(D) Bray-Curtis dissimilarity depicting beta-diversity between *H. pylori* infected and eradicated as well as *H. pylori* infected and non-infected patients. Statistical significance was determined with PERMANOVA. Each symbol represents one patient, shown as bars with mean and standard deviation (SD). Statistical significance was determined with ordinary one-way ANOVA with Tukey's multiple comparisons test in case of normal distribution, otherwise by Kruskal-Wallis-Test with Dunn's multiple comparisons test. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.




Fig. S1:

(A) Experimental setup for infection of *Apc*^{+/min} and *Apc*^{+/1638N} mice.

(B) Colony forming units (CFU) per milligram (mg) stomach tissue of *H. pylori* infected *Apc*^{+/min} mice after 12 weeks of infection and *Apc*^{+/1638N} mice after 24 weeks of infection.

(C) Tumor counts of *H. pylori* infected (n=10) and non-infected (n=8) *Apc*^{+/1638N} mice after 24 weeks of infection in small intestine and colon. Representative pictures showing tumors (circle) of non-infected (Cont.) and infected (*H. pylori*) mice.

Each symbol represents one animal, from 2-3 independent, pooled experiments. Bars denote median. Statistical significance was determined with Mann-Whitney-U test or unpaired t-test, *p < 0.05.




Fig. S2:

- (A) Quantification of CD3+ cells per mm² small intestine and colon tissue is shown for *H. pylori* infected and non-infected *Apc*^{+/-} mice. Pooled data of 3 independent experiments.
- (B) Gating strategy of intestinal lymphocytes. Preliminary lymphocyte gate was applied based on known size and granularity on forward and sideward scatter, followed by exclusion of doublets and dead cells. Afterwards, CD45+ lymphocytes and CD3+ T-cells were selected and subsequent gating was performed on CD4+ or CD8+ T-cells.
- (C) Frequencies of intraepithelial T-cells detected by flow cytometry in small intestine and colon of *H. pylori* infected and non-infected *Apc*^{+/-} mice, gated on live, single cells and CD45+. Representative contour plots are included. Data of one representative experiment of 3 independent experiments is shown.
- (D) Frequencies of T-cell subtypes detected by flow cytometry of *H. pylori* infected and non-infected *Apc*^{+/-} mice, gated on live, single cells, CD45+ and CD3+. Representative pseudocolor plots are included. Pooled data of two independent experiments are shown.
- (E) Mean fluorescence intensity (MFI) of FoxP3+ CD4+ T-cells detected by flow cytometry of *H. pylori* infected and non-infected *Apc*^{+/-} mice, gated on live, single cells, CD45+, CD3+ and CD4+. Data of one representative experiment of 3 independent experiments is shown.
- (F) Colony forming units (CFU) in homogenized stomach tissue of *H. pylori* infected C57BL/6 mice after 24 weeks of infection. Pooled data of 2 independent experiments are shown.
- (G) Fold change in Foxp3 mRNA expression in stomach, small intestine and colon tissue homogenates, normalized to Gapdh and non-infected control mice (2- $\Delta\Delta$ CT value). Pooled data of 2 independent experiments.
- (H) Flow cytometric analysis of intestinal lamina propria lymphocytes isolated from *H. pylori* infected and non-infected *Apc*^{+/-} mice. Paired frequency of IL-17A positive cells of CD4+ T-cells (non-stimulated vs. stimulated with whole *H. pylori* lysate) gated on live, single cells, CD45+ and CD3+, and representative pseudocolor plots of IL-17 releasing CD4+ T-cells are shown. Data of one representative experiment of 2 independent experiments is shown.
- (I) Experimental setup of single-cell RNA sequencing of CD45+ and EPCAM+ cells isolated from small intestine and colon of *H. pylori* infected and non-infected *Apc*^{+/-} mice and *Apc*^{+/+} mice. 2 mice per group were pooled into one sample.
- (J) Unsupervised clustering of immune cells plotted as uniform manifold approximation and projection (UMAP), n=2 mice per group, n= 11407 cells. Leiden clustering and annotated clusters for non-infected and infected mice are shown.
- (K) Gene matrix of marker genes used for annotation of CD45+ clusters.
- (L) Gene matrix of marker genes used for annotation of Treg subclusters.
- (M) RNA velocity analysis plotted as UMAP for single CD3+ T cells from non-infected (left) and *H. pylori* infected *Apc*^{+/-} mice (right). The directional flow of the velocity arrows between cell clusters shows the projection from the observed state to the predicted future state. Zoom into CD4 Treg RNA velocity analysis of *H. pylori* infected and non infected *Apc*^{+/-} mice
- Each symbol represents one animal/single cell, pooled from at least 2 independent experiments (n=6-10 mice/group/experiment) or 2 mice/group for single-cell data. Bars denote median. Unless otherwise specified, statistical significance was determined with student's t-test in case of normal distribution, otherwise by Mann-Whitney U test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.















Fig. S3:

- (A) Unsupervised clustering of epithelial cells plotted as uniform manifold approximation and projection (UMAP), n=2 mice per group, n= 4249 cells. Leiden clustering and annotated clusters for non-infected and infected mice are shown. Clusters for further analysis are highlighted (1= Stem Cells, 2=Enterocytes, 3= goblet cells).
- (B) Gene matrix of marker genes used for annotation of EPCAM+ clusters.
- (C) Pseudo-spatial distribution of stem-cell, enterocyte and tumor cell clusters along the crypt villus axis in small intestine and colon of *Apc*^{+/+} (WT) and *Apc*^{+/-} (APC) mice.
- (D) Gene set score of STAT3 signaling genes, comparing intestinal stem cells from *H. pylori* infected and non-infected *Apc*^{+/+} (WT) and *Apc*^{+/-} (APC) mice.
- (E) Gene set score of NFkB signaling genes, comparing intestinal enterocytes from *H. pylori* infected and non-infected *Apc*^{+/+} (WT) and *Apc*^{+/-} (APC) mice.
- (F) Unsupervised clustering and reannotation of goblet cluster plotted as UMAP, n=218 cells.
- (G) Gene matrix of marker genes used for annotation of goblet cell subclusters.
- (H) Relative frequency of goblet subtypes in *Apc*^{+/+} (WT) and *Apc*^{+/-} (APC) mice, grouped by infection.
- (I) Gene set score of antimicrobial peptide genes, comparing immature goblet cells of small intestine from *H. pylori* infected and non-infected *Apc*^{+/+} (WT) and *Apc*^{+/-} (APC) mice.
- (J) RNA velocity analysis plotted as UMAP for single EPCAM+ cells from non-infected and *H. pylori* infected mice in small intestine and colon. The directional flow of the velocity arrows between cell clusters shows the projection from the observed state to the predicted future state. Squares highlight and zoom in to goblet, paneth cell and colonocytes clusters from non-infected (=1) and infected (=2) colonic epithelial cells.
- (K) Expression of goblet cell differentiation marker *Atoh1* in Colon Stem cells and small intestinal Stem cells, comparing *H. pylori* infected and non-infected mice.
- Each symbol represents one single-cell, pooled from 2 mice/group. Bars denote median. Statistical significance was determined with Kruskal-Wallis test, *p < 0.05, **p < 0.01, ***p < 0.001.




Fig. S4:

(A) Feature counts (ASVs) of *Helicobacter* spp. in stomach of *H. pylori* infected and non-infected C57BL/6 mice (n=6-8mice/group). Data of one representative experiment of 2 independent experiments. Shown as bars with mean and standard deviation (SD). Statistical significance was determined with Mann-Whitney U test, **p < 0.01.

(B) Shannon index depicting alpha-diversity in caecum, stool, small intestine and colon of *H. pylori* infected and non-infected C57BL/6 mice (n=6-8mice/group). Data of one representative experiment of 2 independent experiments. Shown as box and whiskers with (SD). Statistical significance was determined with Mann-Whitney U test, **p < 0.01.

(C) Bray-Curtis dissimilarity depicting beta-diversity of caecum, stool, small intestine and colon between *H. pylori* infected and non-infected C57BL/6 mice (n=6-8mice/group). Data of one representative experiment of 2 independent experiments. Statistical significance was determined with PERMANOVA.

(D) Linear discriminant effect size analysis (LfSe) determining differentially abundant features of caecum, stool, small intestine and colon tissue upon *H. pylori* infection of C57BL/6 mice.









Fig. S5:

- (A) Experimental setup for infection of germ-free *Apc*^{+/-1638N} mice. This preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
- (B) Colony forming units (CFU) per milligram (mg) stomach tissue of *H. pylori* infected germ-free *Apc*^{+/-1638N} mice. Pooled data of two independent experiments (n= 8 mice/group).
- (C) Experimental setup for stool transfer from specific-pathogen free mice (non-infected and *H. pylori* infected *Apc*^{+/+} or *Apc*^{+/-1638N} mice, respectively, (stool donors)) to germ-free *Apc*^{+/-1638N} mice (stool recipients).
- (D) Representative pictures of CD3+, pSTAT3 and PAS stainings from small intestine and colon of non-infected and *H. pylori* germ-free *Apc*^{+/-1638N} mice are shown. White scale bars correspond to 300 μ m in case of small intestine and 200 μ m in case of colon, black scale bars to 20 μ m.
- (E) CFU per mg stomach tissue of *H. pylori* infected and eradicated C57BL/6 and *Apc*^{+/-1638N} mice is shown. Data of one experiment (n=3-6 mice/group).
- (F) Representative pictures of gastric CD3+ staining and quantification of positive intraepithelial cells per mm² of *H. pylori* infected and eradicated C57BL/6 mice are shown. White scale bars correspond to 200 μ m, black scale bars to 20 μ m. Data of one experiment (n= 5-6 mice/group).
- (G) Representative pictures of colonic CD3+, pSTAT3 and PAS stainings from *H. pylori* infected and eradicated C57BL/6 mice are shown. White scale bars correspond to 200 μ m, black scale bars to 20 μ m. Quantification of positive cells per mm² is shown. Data of one experiment (n= 5-6 mice/group).
- Each symbol represents one animal. Bars denote median. Statistical significance was determined with ordinary one- way ANOVA with Tukey's multiple comparisons test in case of normal distribution, otherwise by Kruskal-Wallis-Test with Dunn's multiple comparisons test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.




Fig. S6:

(A) Flow cytometric analysis of colon biopsies from *H. pylori* currently infected, eradicated and non-infected patients were conducted. Frequencies of CD3+ T-cells, gated on live, single cells, CD45+ and CD3+ are shown and representative contour plots of *H. pylori* currently infected and negative individuals are included.

(B) Frequencies of T-cell subsets CD4 and CD8, gated on live, single cells, CD45+ and CD3+ are shown and representative pseudocolor plots of *H. pylori* currently infected and negative individuals are included.

(C) Overview of colon tissue stained with multiplexed chip cytometry. Automatic image processing of multiplexed chip cytometry on human colon tissue determines CD45+, CD3+, CD4+ and FoxP3+ cells and their location. Large scale bar corresponds to 500µm.

(D) Shannon index as indicator of alpha-diversity of stool samples from *H. pylori* currently infected, eradicated and non-infected individuals are shown. Data shown as box and whiskers with SD.

(E) Ratio of the phyla Firmicutes to Bacteroidetes, shown as bars with mean and SD.

(F) Linear discriminant effect size analysis (LEfSe) determining differentially abundant features of stool samples from *H. pylori* negative and positive individuals. Interesting features are highlighted in black.

(G) Feature counts of *Prevotella* spp. of stool samples *H. pylori* currently infected, eradicated and non-infected individuals, shown as bars with mean and SD.

Each symbol represents one patient. Statistical significance was determined with ordinary one-way ANOVA with Tukey's multiple comparisons test in case of normal distribution, otherwise by Kruskal-Wallis-Test with Dunn's multiple comparisons test.